This study assessed plazomicin’s in-vitro efficacy against colistin-resistant Enterobacteriaceae, including mcr-1 producers. It concluded that plazomicin showed superior susceptibility compared to other aminoglycosides across resistance types.
A 79-year-old woman with COPD developed pulmonary co-infection with Mycobacterium tuberculosis and Nocardia farcinica. Treatment with anti-TB regimen and TMP/SMX led to clinical improvement with resolution of fever and respiratory symptoms.